Corbus Believes A Different Inflammation-Fighting Approach Will Serve All CF Patients
This article was originally published in The Pink Sheet Daily
The start-up asserts that agonizing the CB2 receptor will “resolve” inflammation, a different approach than used by anti-inflammatory drugs, and one that would pertain to the entire cystic fibrosis patient population.
You may also be interested in...
Safety was the primary endpoint in a Phase II study for the inflammation-targeting drug anabasum, but Corbus believes an efficacy signal viewed outside of the secondary endpoints justifies further development.
Cystic Fibrosis Market Snapshot: Disease-Modifying Drugs Elusive 24 Years After Discovery Of Root Cause
The discovery in 1989 of the underlying genetics causing cystic fibrosis was expected to spur broad development of disease-modifying therapies. As of 2013, however, only one such drug is on the market, for a small subset of CF patients, and a few other candidates are in clinical development.
The median review time for novel agents at CDER hasn’t changed in five years. Our infographic offers a look at the tortoises and hares (all of them winners because they got approved).